In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

  

onartuzumab 
A humanized monovalent monoclonal antibody directed against the hepatocyte growth factor receptor (c-Met) with potential antineoplastic activity. Onartuzumab binds to the extracellular domain of c-Met, preventing the binding of its ligand, hepatocyte growth factor (HGF); the activation of the c-Met signaling pathway is thus inhibited, which may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase, is overexpressed on the cell surfaces of a variety of cancer cell types and may play a key role in their proliferation, invasion and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:anti-MET monoclonal antibody MetMAb
Code names:MetMAb
RO5490258